PHAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PHAT is not a good buy right now for an impatient buyer. The setup is still technically weak (MACD below zero, RSI depressed), and the pattern-based outlook points to near-term downside (model suggests ~-3.09% next day, -1.5% next week, -5.54% next month). While options positioning is aggressively call-skewed and analysts see upside vs. the current ~$13.6, there is no proprietary buy signal today and no fresh news catalyst to force an immediate re-rating. Net: wait/hold rather than buy at the open.
Trend/Momentum: MACD histogram at -0.166 (below 0) but negatively contracting, which can indicate selling pressure is easing, not that an uptrend has started. RSI(6) ~35.84 is near oversold but still classified as neutral here—suggesting weakness without a confirmed reversal. Moving averages are converging, consistent with consolidation after a decline rather than a clean uptrend. Key levels: Current pre-market ~13.62 is below the pivot 14.099 (bearish bias under pivot). Nearby support S1=13.335 (break below increases risk toward S2=12.863). Resistance levels: 14.863 (R1) then 15.335 (R2). For an immediate buy, price is still in the lower zone under the pivot with downside risk to support.
Analyst upside: New coverage includes Raymond James Strong Buy with $28 target (large upside vs ~$13.6), citing Voquezna differentiation and expense rationalization.
Business momentum: 2025/Q3 revenue surged +202.74% YoY and gross margin expanded to ~87.5%, supporting a stronger commercial trajectory.
Options sentiment: Strong call-skew and volume spike suggest the market is positioning for upside or a rebound.
with downside risk to S1/S2; no clear reversal signal yet.
Latest quarter: 2025/Q3. Revenue rose to $49.50M (+202.74% YoY), and gross margin improved to 87.5% (+2.23% YoY), indicating strong product economics and accelerating sales. However, profitability deteriorated: net income was -$29.97M (down -64.98% YoY as provided) and EPS -0.41 (down -68.94% YoY), implying operating costs/other expenses are still outweighing the revenue ramp. Growth is impressive, but the market may continue to demand clearer progress toward narrowing losses.
Recent rating/target trend: Coverage initiations in Dec 2025 are mixed-to-positive. Barclays initiated Equal Weight with $16 target (modest upside), while Raymond James initiated Strong Buy with $28 target (high-conviction upside) based on Voquezna’s differentiation and cost rationalization. Wall Street pros: Strong product positioning (first/only FDA-approved PCAB for GERD), accelerating revenue, high gross margin, and a refocused commercial strategy. Wall Street cons: Still-lossmaking with worsening EPS/net income metrics in the latest quarter; execution risk in commercialization and the need to translate revenue growth into improving bottom-line trend. Influential/political trading: No recent congress trading data available; hedge fund and insider trends listed as Neutral with no significant recent activity.
